Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scivision BiotechTPE:1786 +1.61%75 FCF Margin % is 30.01% as of Jun. 2026, which is 238% above its 10-year median of 8.87. GuruFocus rates TPE:1786 with a GF Score™ of 75/100 and a GF Value™ of NT$101.14 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 813 Medical Devices & Instruments companies, Scivision Biotech ranks better than 64.7% on this metric.
The historical rank and industry rank for Scivision Biotech's FCF Margin % or its related term are showing as below:
TPE:1786'
s FCF Margin % Range Over the Past 10 Years
Min: -119.3 Med: 8.87 Max: 36.07
Current: 5.91
During the past 13 years, the highest FCF Margin % of Scivision Biotech was 36.07%. The lowest was -119.30%. And the median was 8.87%.
TPE:1786's FCF Margin % is ranked better than 64.7% of 813
companies
in the Medical Devices & Instruments industry
Industry Median: -0.8
vs TPE:1786: 5.91
The historical data trend for Scivision Biotech's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1786 vs ISRG, BDX, MDLN: FCF Margin % Comparison
For the Medical Instruments & Supplies subindustry, Scivision Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scivision Biotech FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Scivision Biotech's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Scivision Biotech's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scivision Biotech (TPE:1786) has a FCF Margin % of 30.01% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Scivision Biotech and its competitors. This is 238% above median its historical median of 8.87. According to the industry distribution chart, Scivision Biotech ranks #287 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 35.3%.
Is Scivision Biotech's FCF Margin % too high?
Scivision Biotech's current FCF Margin % of 30.01% is 238% above median its 10-year median of 8.87. Based on the distribution chart, Scivision Biotech ranks #287 out of 813 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Scivision Biotech has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scivision Biotech's FCF Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Scivision Biotech ranks #287 out of 813 companies for FCF Margin %. This puts Scivision Biotech in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Scivision Biotech and its competitors. Scivision Biotech's current FCF Margin % is 30.01%, which is 238% above median its own 10-year median of 8.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scivision Biotech stock overvalued right now?
Based on GuruFocus' analysis, Scivision Biotech (TPE:1786) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$101.14, compared to a current price of NT$50.40 — trading 50.2% below its estimated fair value. The current FCF Margin % is 30.01%, which is 238% above median its 10-year median of 8.87. Scivision Biotech's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Scivision Biotech (TPE:1786), the current FCF Margin % is 30.01% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scivision Biotech (TPE:1786) Overvalued in 2026?
Based on GuruFocus' analysis, Scivision Biotech stock appears to be undervalued.
The current stock price of NT$50.40 is trading 50.2% below its estimated GF Value™ of NT$101.14.
GuruFocus considers Scivision Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1786:
FCF Margin %: 30.01% (238% above median its 10-year median of 8.87)
GF Value™: NT$101.14 vs. price of NT$50.40 (50.2% below fair value)
No single metric tells the full story. See the TPE:1786 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scivision Biotech Inc is engaged in the manufacturing and distribution of hyaluronic acid medical supplies in Taiwan. It offers medical devices, including absorbable adhesion barriers, dermal implants, synovial fluid supplements, and intravesical instillation.
75GF Score
Get the complete analysis for TPE:1786
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1786 has been successfully added to your 
